Sector News

Roquette to acquire Qualicaps

July 30, 2023
Life sciences

French plant ingredients supplier Roquette, which is also is a leading player in naturally-derived pharmaceutical excipients, has agreed to acquire Qualicaps, a producer of hard capsules and pharmaceutical processing equipment for oral dosage.

The transaction is expected to close in the fourth quarter of 2023 but remains subject to the fulfillment of some customary and legal conditions. Financial details were not disclosed.

Qualicaps, part of Mitsubishi Chemical, is headquartered in Nara, Japan, and is the third largest producer of hard capsules for oral dosage solutions. The company has 1,400 employees located in sites in Asia, Europe and the Americas, and its client base includes major pharmaceutical and food companies around the world.

Roquette commented that this strategic investment offers the ability to expand the global footprint of its pharmaceutical business, as well as enrich its offerings of oral dosage solutions.

The newly combined businesses will offer the most diverse range of oral dosage solutions to existing and new customers, said Roquette.

Pierre Courduroux, CEO of Roquette, said: “Today’s announcement is a significant step in Roquette’s journey to reinforce its position as a key player in Health and Nutrition markets. Qualicaps’ strong position in hard capsules will represent a significant addition to our excipients’ portfolio and will enable our company to offer more solutions responding to the needs of our customers and to the demands of patients who are looking for continuously better treatments.”

Source: chemanager-online.com

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach